These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 30368587)

  • 1. Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma.
    Wu FT; Lu L; Xu W; Li JY
    Ann Hematol; 2019 Feb; 98(2):255-269. PubMed ID: 30368587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
    Cherng HJ; Herrera A
    Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse large B-cell lymphoma: Time to focus on circulating blood nucleic acids?
    Regazzo G; Marchesi F; Spagnuolo M; Díaz Méndez AB; Masi S; Mengarelli A; Rizzo MG
    Blood Rev; 2021 May; 47():100776. PubMed ID: 33229139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid biopsy in tissue-born lymphomas.
    Spina V; Rossi D
    Swiss Med Wkly; 2019 Jan; 149():w14709. PubMed ID: 30673117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
    Scherer F; Kurtz DM; Newman AM; Stehr H; Craig AF; Esfahani MS; Lovejoy AF; Chabon JJ; Klass DM; Liu CL; Zhou L; Glover C; Visser BC; Poultsides GA; Advani RH; Maeda LS; Gupta NK; Levy R; Ohgami RS; Kunder CA; Diehn M; Alizadeh AA
    Sci Transl Med; 2016 Nov; 8(364):364ra155. PubMed ID: 27831904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas.
    Arffman M; Meriranta L; Autio M; Holte H; Jørgensen J; Brown P; Jyrkkiö S; Jerkeman M; Drott K; Fluge Ø; Björkholm M; Karjalainen-Lindsberg ML; Beiske K; Pedersen MØ; Leivonen SK; Leppä S
    Med; 2024 Jun; 5(6):583-602.e5. PubMed ID: 38579729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.
    Kurtz DM; Scherer F; Jin MC; Soo J; Craig AFM; Esfahani MS; Chabon JJ; Stehr H; Liu CL; Tibshirani R; Maeda LS; Gupta NK; Khodadoust MS; Advani RH; Levy R; Newman AM; Dührsen U; Hüttmann A; Meignan M; Casasnovas RO; Westin JR; Roschewski M; Wilson WH; Gaidano G; Rossi D; Diehn M; Alizadeh AA
    J Clin Oncol; 2018 Oct; 36(28):2845-2853. PubMed ID: 30125215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
    Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
    Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid biopsy in diffuse large B-cell lymphoma: utility in cell origin determination and survival prediction in Chinese patients.
    Li M; Ding N; Mi L; Shi Y; Du X; Yi Y; Yang L; Liu W; Zhu J
    Leuk Lymphoma; 2022 Mar; 63(3):608-617. PubMed ID: 34751093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical Application and Research Progress of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma--Review].
    Zhang HY; Yang YL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1917-1921. PubMed ID: 36476926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential.
    Camus V; Jardin F; Tilly H
    Expert Rev Mol Diagn; 2017 Jun; 17(6):557-566. PubMed ID: 28415895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical Application of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma--Review].
    Chen XF; Wang M; Zhang F; Li JJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):638-642. PubMed ID: 33812444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma circulating tumour DNA is a better source for diagnosis and mutational analysis of IVLBCL than tissue DNA.
    Chen C; Di Y; Zhuang Z; Cai H; Jia C; Wang W; Zhao D; Wei C; Zhang W; Zhou D; Zhang Y
    J Cell Mol Med; 2024 Jul; 28(14):e18576. PubMed ID: 39054569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma.
    Hu R; Winter A; Hill BT
    Curr Oncol Rep; 2019 Apr; 21(5):44. PubMed ID: 30941515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates on Circulating Tumor DNA Assessment in Lymphoma.
    Darrah JM; Herrera AF
    Curr Hematol Malig Rep; 2018 Oct; 13(5):348-355. PubMed ID: 30136210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-Matched IgH Gene Rearrangement of Circulating Tumor DNA Shows Significant Value in Predicting the Progression of Diffuse Large B Cell Lymphoma.
    Zhao K; Zheng X; Liu X; Liu T; Ke Z; Zhu F; Wen Q; Xin B; Li Q; Zhang L
    Oncologist; 2024 May; 29(5):e672-e680. PubMed ID: 38297976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma.
    Liang JH; Wu YF; Shen HR; Li Y; Liang JH; Gao R; Hua W; Shang CY; Du KX; Xing TY; Zhang XY; Wang CX; Zhu LQ; Shao YW; Li JY; Wu JZ; Yin H; Wang L; Xu W
    Leukemia; 2024 Jul; 38(7):1541-1552. PubMed ID: 38750139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Monitoring of Cell-Free Circulating Tumor DNA in Non-Hodgkin Lymphoma.
    Melani C; Roschewski M
    Oncology (Williston Park); 2016 Aug; 30(8):731-8, 744. PubMed ID: 27539624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.
    Li M; Mi L; Wang C; Wang X; Zhu J; Qi F; Yu H; Ye Y; Wang D; Cao J; Hu D; Yang Q; Zhao D; Ma T; Song Y; Zhu J
    BMC Med; 2022 Oct; 20(1):369. PubMed ID: 36280874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL.
    Tabari E; Lovejoy AF; Lin H; Bolen CR; Lor Saelee S; Lefkowitz JP; Kurtz DM; Bottos A; Nielsen TG; Parreira JM; Luong KT
    Leuk Lymphoma; 2024 May; 65(5):618-628. PubMed ID: 38337191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.